Clinical Trials Logo

Hypoxia clinical trials

View clinical trials related to Hypoxia.

Filter by:

NCT ID: NCT03085771 Recruiting - Clinical trials for Diabetes Mellitus, Type 1

Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes

DESIRED
Start date: January 1, 2017
Phase: Phase 2
Study type: Interventional

The general aim of this study is to investigate the influence of systemic administration of Desferal (Deferoxamine [DFO]) on the response to hypoxic challenge in patients with diabetes mellitus (DM). The investigation will elucidate if DFO can restore: - the impaired angiogenetic response to hypoxia in patients with type 1 DM. - the disturbed respiratory and cardiovascular regulation in response to hypoxia in patients with DM type 1

NCT ID: NCT03079167 Completed - Clinical trials for Hypoxic-Ischemic Encephalopathy

PAEAN - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns

PAEAN
Start date: May 14, 2016
Phase: Phase 3
Study type: Interventional

Double-blind, placebo controlled Phase III trial of erythropoietin for hypoxic ischaemic encephalopathy in infants receiving hypothermia. The study aim is to determine whether Epo in conjunction with hypothermia in infants with moderate/severe hypoxic ischaemic encephalopathy (HIE) will improve neurodevelopmental outcomes at 2 years of age, without significant adverse effects, when compared to hypothermia alone.

NCT ID: NCT03071393 Completed - Clinical trials for Spinal Cord Injuries

Intermittent Hypoxia to Enhance Motor Function After Spinal Cord Injury

Start date: July 10, 2017
Phase: N/A
Study type: Interventional

This study will examine if acute intermittent hypoxia (brief episodes of breathing lower oxygen), which has been shown to enhance plasticity and motor output, can enhance functional outcomes and muscle activation in individuals with spinal cord injury. Our aim is to assess breathing, sitting, standing and walking functional ability before and after acute intermittent hypoxia, compared to a sham treatment. This information may be useful in advancing rehabilitation for people with spinal cord injuries.

NCT ID: NCT03066115 Withdrawn - Hypoxia Clinical Trials

Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation

Start date: December 1, 2020
Phase: Phase 1
Study type: Interventional

Elucidating cerebrovascular control mechanisms during physiologic stress may help identify novel therapeutic targets aimed at preventing or reducing the impact of cerebrovascular disease. The physiological stressors of hypoxia and hypercapnia will be utilized to elicit increases in cerebral blood flow (CBF), and intravenously infused drugs will allow for the testing of potential mechanisms of cerebrovascular control. Specifically, the contributions of nitric oxide synthase (NOS), cyclooxygenase (COX), and reactive oxygen species (ROS) to hypoxic and hypercapnic increases in CBF will be examined. The concept that these mechanisms interact in a compensatory fashion to ensure adequate CBF during both hypoxia and hypercapnia will also be tested. ~25 young, healthy men and women will be tested at rest and during hypoxia and hypercapnia. Subjects will participate in two randomized, counterbalanced study visits under the following conditions: inhibition of NOS, NOS-COX, and NOS-COX-ROS or inhibition of COX, COX-NOS, COX-NOS-ROS. During hypoxia, arterial oxygen saturation will be lowered to 80% and end-tidal carbon dioxide will be maintained at basal levels. During hypercapnia arterial carbon dioxide will be increased ~10 mmHg above basal levels and arterial oxygen saturation will be maintained. Blood flow velocity will be measured with transcranial Doppler ultrasound in the anterior (middle cerebral artery; MCA) and posterior (basilar artery; BA) circulations as a surrogate for CBF. It is hypothesized that both NOS and COX independently contribute to hypoxic and hypercapnic vasodilation in the MCA and BA, combined NOS-COX contribute to hypoxic and hypercapnic vasodilation in MCA and BA to a greater extent than either NOS or COX alone, and NOS-COX-ROS contribute to hypoxic and hypercapnic vasodilation in the MCA and BA to a greater extent than NOS-COX.

NCT ID: NCT03054792 Enrolling by invitation - Rhabdomyosarcoma Clinical Trials

Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas

Start date: May 1, 2017
Phase: Phase 1
Study type: Interventional

This study will test the feasibility of using novel/existing imaging technologies focused on hypoxia measurements to determine "response to therapy" in pediatric soft tissue sarcomas as a pilot study. Specifically, the investigators will compare the sensitivity of Blood Oxygen Level Dependent [BOLD], Diffusion-Weighted [DW] MRI, Magnetic Resonance Spectroscopy (MRS) and 18F-FAZA PET-MRI with that of conventional MRI to detect measurement changes between the start and completion of neoadjuvant therapy ("response to therapy") in children and adolescents (7-18 years) with suspicion of sarcoma tumors. Clinicians and scientists may use results of the proposed hypoxia-imaging surrogate markers to adjust/modify therapeutic schemes to patients on a personalized basis.

NCT ID: NCT03051711 Terminated - Clinical trials for Cardio-pulmonary Function

Study to Evaluate Effects of Investigational Drug on Oxygenation in Healthy Volunteers Under Hypoxic Conditions

Start date: December 2016
Phase: Phase 1
Study type: Interventional

To evaluate the effect of GBT440 on oxygen saturation at rest and exercise, under hypoxic conditions, at Day 15 compared to Baseline.

NCT ID: NCT03040570 Completed - Hypoxia Clinical Trials

Conservative Versus Liberal Oxygenation Targets in Critically Ill Children

Oxy-PICU
Start date: March 4, 2017
Phase: N/A
Study type: Interventional

A feasibility study to determine if it is possible to perform a safe, adequately powered, and affordable multi-centre study in critically ill children comparing current practice of liberal targets for systemic oxygen levels with more conservative targets.

NCT ID: NCT03029559 Completed - Clinical trials for Intermittent Hypoxia

Intermittent Hypoxia and Inspiratory Threshold Loading to Enhance Inspiratory Muscle Function

Start date: February 17, 2017
Phase: N/A
Study type: Interventional

Rehabilitation approaches introduce a stimulus to a motor system, with the goal to enhance motor function to patients. For example, exposure to brief and intermittent episodes of mild hypoxia has shown to strengthen synaptic pathways to respiratory and skeletal muscle motor neurons. In humans with spinal cord injury, exposure to intermittent hypoxia (IH) alone or in combination with rehabilitative strategies has shown enhanced motor function. Another strategy known as inspiratory threshold loading, which involves breathing against pressure threshold loads, results in improved inspiratory muscle strength. Although there is evidence supporting the use of IH alone or in combination with other rehabilitative strategies in improving motor function in humans, the impact of exposure to IH or IH with inspiratory threshold loading on inspiratory muscle function and ventilation in humans is unknown.

NCT ID: NCT03026322 Completed - Respiratory Failure Clinical Trials

Preventing Hypoxemia With Manual Ventilation During Endotracheal Intubation (PreVent) Trial

PreVent
Start date: March 15, 2017
Phase: N/A
Study type: Interventional

Complications are common during endotracheal intubation of critically ill adults. Manual ventilation between induction and intubation ("bag-valve-mask" ventilation) has been proposed as a means of preventing hypoxemia, the most common complication of intubation outside the operating room. Safety and efficacy data, however, are lacking. PreVent is a randomized trial comparing manual ventilation between induction and laryngoscopy to no manual ventilation between induction an laryngoscopy during endotracheal intubation of critically ill adults. The primary efficacy endpoint will be the lowest arterial oxygen saturation. The primary safety endpoints will be the lowest oxygen saturation, highest fraction of inspired oxygen, and highest positive end-expiratory pressure in the 24 hours after the procedure.

NCT ID: NCT03021824 Completed - Clinical trials for Acute Respiratory Distress Syndrome

Severe ARDS: Generating Evidence

SAGE
Start date: October 1, 2016
Phase:
Study type: Observational

An assessment of early management of moderate-severe ARDS in the United States, including ventilator management and use of rescue therapy.